Fig. 2: Flow diagram of the clinical trial and the process of CAR-NK manufacture. | Nature Cancer

Fig. 2: Flow diagram of the clinical trial and the process of CAR-NK manufacture.

From: Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a phase 1 trial

Fig. 2

a, Consolidated Standards of Reporting Trials flow chart summarizing the number of participants screened, enrolled, treated, and followed in the study. b, CBMCs were isolated from the umbilical cord blood by Ficoll density gradient centrifugation, and CD3+ T cells were depleted using CD3 microbeads. CD3− CBMCs were stored as seed cells. When CAR-NK cells were manufactured, CD3− CBMC seed cells were thawed and underwent two-cycle feed-cell stimulation and CAR transduction before infusion. FC represents fludarabine combined with cyclophosphamide.

Back to article page